{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:17:56Z","timestamp":1794374276144,"version":"4.9.0"},"reference-count":39,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T00:00:00Z","timestamp":1633305600000},"content-version":"unspecified","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Natural Science Foundation of China grants","award":["81971496"],"award-info":[{"award-number":["81971496"]}]},{"name":"Natural Science Foundation of China grants","award":["81971536"],"award-info":[{"award-number":["81971536"]}]},{"name":"Fujian Science and Technology Project","award":["2020J011250"],"award-info":[{"award-number":["2020J011250"]}]},{"name":"Fujian Science and Technology Project","award":["2020J05309"],"award-info":[{"award-number":["2020J05309"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2021,9,16]]},"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Primary immune thrombocytopaenia (ITP) is highly heterogeneous. ANA-positive primary ITP may resemble the preclinical stage of connective tissue diseases (CTDs), but is still considered primary ITP due to a controversial CTD risk assessment in this group. The objective of this study was to clarify the risk of CTD in ANA-positive patients with primary ITP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective cohort study and a meta-analysis. 586 patients with newly diagnosed primary ITP were followed up and Cox regression analyses were used to analyse the associations of ANA positivity and other immune parameters with CTD development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean follow-up time was 37 (19\u201356) months. ANA was positive in 21.33% (125 of 586) of patients with primary ITP in our retrospective cohort, and the overall rate of ANA positivity in the meta-analysis was 17.06% (369 of 2163). The adjusted HR for CTD in ANA-positive primary ITP was 6.15 (95% CI 2.66 to 14.23, p&lt;0.001). Five patients in the ANA-positive group developed SLE (5 of 125, 4.0%), significantly higher than in the ANA-negative group (0 of 461, 0%). A clinical model combining ANA, anti-Sjogren\u2019s syndrome A antibody and C3 was successfully developed to predict the risk of CTD in patients with primary ITP. Increased risk of CTD (risk ratio=12.43, 95%\u2009CI 7.91 to 19.55, p&lt;0.00001), especially SLE (risk ratio=30.41, 95%\u2009CI 13.23 to 69.86, p&lt;0.00001), among ANA-positive patients with primary ITP was confirmed by a meta-analysis of previous studies and the present study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The findings suggest that ANA-positive primary ITP is a clinical entity distinct from other primary ITPs and is associated with increased risk of developing CTDs, especially SLE.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/lupus-2021-000523","type":"journal-article","created":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T18:21:30Z","timestamp":1633458090000},"page":"e000523","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":24,"title":["ANA-positive primary immune thrombocytopaenia: a different clinical entity with increased risk of connective tissue diseases"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2668-0350","authenticated-orcid":false,"given":"Yuan","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China"},{"name":"School of Medicine, Xiamen University, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiju","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China"},{"name":"School of Medicine, Xiamen University, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guomei","family":"Yang","sequence":"additional","affiliation":[{"name":"School of Medicine, Xiamen University, Xiamen, China"},{"name":"Department of Rheumatology, The Affiliated Hospital of Southwest Medical University, Luzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinying","family":"Lan","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China"},{"name":"School of Medicine, Xiamen University, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China"},{"name":"School of Medicine, Xiamen University, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peishi","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China"},{"name":"School of Medicine, Xiamen University, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puqi","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China"},{"name":"School of Medicine, Xiamen University, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China"},{"name":"School of Medicine, Xiamen University, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4044-3394","authenticated-orcid":false,"given":"Guixiu","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China"},{"name":"School of Medicine, Xiamen University, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,10,5]]},"reference":[{"key":"2025091514230124000_8.1.e000523.1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-162503"},{"key":"2025091514230124000_8.1.e000523.2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-129155"},{"key":"2025091514230124000_8.1.e000523.3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-754119"},{"key":"2025091514230124000_8.1.e000523.4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-223305"},{"key":"2025091514230124000_8.1.e000523.5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-302984"},{"key":"2025091514230124000_8.1.e000523.6","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780251101"},{"key":"2025091514230124000_8.1.e000523.7","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21591"},{"key":"2025091514230124000_8.1.e000523.8","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F"},{"key":"2025091514230124000_8.1.e000523.9","doi-asserted-by":"crossref","DOI":"10.1002\/art.38098","article-title":"Classification criteria for systemic sclerosis: an ACR-EULAR collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2025091514230124000_8.1.e000523.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502132920706"},{"key":"2025091514230124000_8.1.e000523.11","first-page":"615","article-title":"Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria","volume":"17","author":"Mosca","year":"1999","journal-title":"Clin Exp Rheumatol"},{"key":"2025091514230124000_8.1.e000523.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06635.x"},{"key":"2025091514230124000_8.1.e000523.13","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830320205"},{"key":"2025091514230124000_8.1.e000523.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780280527"},{"key":"2025091514230124000_8.1.e000523.15","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine1962.29.481"},{"key":"2025091514230124000_8.1.e000523.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)80342-8"},{"key":"2025091514230124000_8.1.e000523.17","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199707000-00006"},{"key":"2025091514230124000_8.1.e000523.18","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1055\/s-0037-1613754","article-title":"Screening for autoimmune markers is unnecessary during follow-up of adults with autoimmune thrombocytopenic purpura and NO autoimmune markers at onset","volume":"83","author":"Vantelon","year":"2000","journal-title":"Thromb Haemost"},{"key":"2025091514230124000_8.1.e000523.19","doi-asserted-by":"publisher","DOI":"10.1007\/s002770100306"},{"key":"2025091514230124000_8.1.e000523.20","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20299"},{"key":"2025091514230124000_8.1.e000523.21","first-page":"34","article-title":"Chronic idiopathic thrombocytopenic purpura in adult Chinese patients: a retrospective single-centered analysis of 1791 cases","volume":"118","author":"Li","year":"2005","journal-title":"Chin Med J"},{"key":"2025091514230124000_8.1.e000523.22","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20970"},{"key":"2025091514230124000_8.1.e000523.23","article-title":"The antiphospholipid antibodies, a risk factor to developed antiphospholipide syndrome or systemic lupus Erythematous in the patients with immune thrombocytopenic purpura (ITP)","volume":"98","author":"Gaman","year":"2013","journal-title":"Haematologica"},{"key":"2025091514230124000_8.1.e000523.24","first-page":"840","article-title":"Risk of lupus after primary immune thrombocytopenic purpura: a 14 year single center experience","volume":"102","author":"Ayesh","year":"2017","journal-title":"Haematologica"},{"key":"2025091514230124000_8.1.e000523.25","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2014-000078"},{"key":"2025091514230124000_8.1.e000523.26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217013"},{"key":"2025091514230124000_8.1.e000523.27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215089"},{"key":"2025091514230124000_8.1.e000523.28","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002818"},{"key":"2025091514230124000_8.1.e000523.29","doi-asserted-by":"publisher","DOI":"10.1177\/0961203307078579"},{"key":"2025091514230124000_8.1.e000523.30","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.201589"},{"key":"2025091514230124000_8.1.e000523.31","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-007-0031-y"},{"key":"2025091514230124000_8.1.e000523.32","first-page":"184","article-title":"High-Titer antinuclear antibodies, anti-SSA\/Ro antibodies and anti-nuclear RNP antibodies in patients with idiopathic thrombocytopenic purpura","volume":"71","author":"Kurata","year":"1994","journal-title":"Thromb Haemost"},{"key":"2025091514230124000_8.1.e000523.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2009.11.014"},{"key":"2025091514230124000_8.1.e000523.34","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3109\/08820139309063402","article-title":"Clinical relevance of antibodies to Ro\/SS-A and La\/SS-B in subacute cutaneous lupus erythematosus and related conditions","volume":"22","author":"Zappi","year":"1993","journal-title":"Immunol Invest"},{"key":"2025091514230124000_8.1.e000523.35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021933"},{"key":"2025091514230124000_8.1.e000523.36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00444","article-title":"Diagnostic utility of separate Anti-Ro60 and Anti-Ro52\/TRIM21 antibody detection in autoimmune diseases","volume":"10","author":"Robbins","year":"2019","journal-title":"Front Immunol"},{"key":"2025091514230124000_8.1.e000523.37","doi-asserted-by":"crossref","first-page":"312","DOI":"10.11604\/pamj.2015.22.312.6839","article-title":"Isolated anti-Ro\/SSA thrombocytopenia: a rare feature of neonatal lupus","volume":"22","author":"Ayadi","year":"2015","journal-title":"Pan Afr Med J"},{"key":"2025091514230124000_8.1.e000523.38","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-103-4-548"},{"key":"2025091514230124000_8.1.e000523.39","doi-asserted-by":"publisher","DOI":"10.1177\/1076029610387588"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2021-000523","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T21:23:08Z","timestamp":1757971388000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2021-000523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,10,5]]},"published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1136\/lupus-2021-000523"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2021-000523","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10]]}}}